首页|Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

扫码查看
原文链接
  • NETL
  • NSTL
  • 维普
  • 万方数据
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome,hypercoagulability,hypertension,and multiorgan dysfunction.Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis.In an analysis of a randomly collected cohort of 124 patients with COVID-19,we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity.By virtual screening of a U.S.FDA approved drug library,we identified an anticoagulation agent dipyridamole (DIP) in silico,which suppressed SARS-CoV-2 replication in vitro.In a proof-of-concept trial involving 31 patients with COVID-19,DIP supplementation was associated with significantly decreased concentrations of D-dimers (P ＜ 0.05),increased lymphocyte and platelet recovery in the circulation,and markedly improved clinical outcomes in comparison to the control patients.In particular,all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5％) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5％) was in clinical remission.

DipyridamoleSARS-CoV-2COVID-19TreatmentD-dimerSevere cases

Xiaoyan Liu、Zhe Li、Shuai Liu、Jing Sun、Zhanghua Chen、Min Jiang、Qingling Zhang、Yinghua Wei、Xin Wang、Yi-You Huang、Yinyi Shi、Yanhui Xu、Huifang Xian、Fan Bai、Changxing Ou、Bei Xiong、Andrew M.Lew、Jun Cui、Rongli Fang、Hui Huang、Jincun Zhao、Xuechuan Hong、Yuxia Zhang、Fuling Zhou、Hai-Bin Luo

展开 >

Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences,Sun Yat-sen University, Guangzhou 510006, China

Dawu County People's Hospital, Xiaogan 432826, China

State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120, China

Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China

Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871,China

Department of Infectious Disease and Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Center for Innovative Marine Drug Screening & Evaluation (QNLM), School of Medicine and Pharmacy, Ocean University of China, Qingdao 266100, China

Walter and Eliza Hall Institute of Medical Research and Department of Microbiology & Immunology, University of Melbourne, Parkville, Vic 3052, Australia

School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China

Cardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China

State Key Laboratory of Virology, College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lhasa 850000, China

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China

展开 >

We cordially acknowledge Tencent Cloud and National Super-computing centers in Guangzhou,Shenzhen,and Tianjin,China for providin

2020

药学学报(英文版)

药学学报(英文版)

CSTPCDCSCDSCI
ISSN：
年,卷(期)：2020.10(7)
  • 7
  • 2